The IVDR-compliant BÜHLMANN GanglioCombi® MAG ELISA sets a new standard for investigating autoimmune-related peripheral neuropathies by combining MAG and ganglioside antigens in a unique multiparametric IVD ELISA. This innovative kit includes a comprehensive antigen profile: «MAG», GM1, GT1a, GD1a, GD1b, and GQ1b.
Neurologists and laboratories benefit from its efficient, cost-effective, and streamlined workflow, enabling targeted screening for prominent immune-mediated neuropathies in just two easy steps. The kit comes complete with all enzyme label-conjugates, ensuring a thorough and economical work-up.
Test results are categorized as negative, positive, or equivocal, aligning with the nuanced interpretation required in autoimmunology. A positive MAG (IgM) result can suggest MAG neuropathy or MGUS (monoclonal gammopathy of unknown significance) and may be further confirmed with the gold-standard anti-MAG Antibodies ELISA, providing confidence and clarity for clinical decision-making.
Method | ELISA |
Analytes | anti-MAG* and –Ganglioside antibodies (GM1, GT1a, GD1a, GD1b, GQ1b) |
Time to Result | 4.5 h (approx.) |
Sample type and -volume | serum; 100 uL (1:50) |
Enzyme-labels | IgG/IgM Mix, IgM and IgG |
Results | % Ratio of Calibrator |
Cut-off | 50% |
Order Code | EK-GCM |
CE (IVDR compliant) |
* Chemically synthesized HNK-1 epitope of the MAG glycoprotein
BÜHLMANN Laboratories AG
Baselstr. 55
4124 Schönenbuch
Switzerland
Phone: +41 61 487 12 12
E-Mail: info@buhlmannlabs.ch
Social Links